Enzymatic preparation of κ-carrageenan oligosaccharides and their anti-angiogenic activity

被引:79
作者
Yao, Ziang [1 ]
Wu, Haige [1 ,2 ]
Zhang, Shengxia [1 ]
Du, Yuguang [2 ]
机构
[1] Dalian Univ, Sch Life Sci & Technol, Dalian 116622, Peoples R China
[2] Chinese Acad Sci, Dalian Inst Chem Phys, Dalian 116023, Peoples R China
基金
中国国家自然科学基金;
关键词
kappa-Carrageenan oligosaccharides; Anti-tumor; Anti-angiogenesis; CD; 105; IN-VITRO; INHIBITS ANGIOGENESIS; THERAPY; GROWTH; TUMOR; GIGARTINALES; ANTITUMOR; FRACTION; TARGETS; CANCER;
D O I
10.1016/j.carbpol.2013.09.055
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
The mixture of kappa-neocarrabiose-sulfate, kappa-neocarrahexaose-sulfate and kappa-neocarraoctaose-sulfate were prepared from kappa-carrageenan with enzyme. The anti-tumor and anti-angiogenic activity of obtained kappa-carrageenan oligosaccharides (KOS), were explored. The results showed that KOS could inhibit the proliferation, migration and tube formation of ECV304 cells, and could inhibit the growth of new vessels in CAM model. KOS displayed strong anti-tumor activity in both S180 and MCF-7 xenograft models. Only human CD105 was detected in MCF-7 xenograft tumor, moreover KOS could decrease the growing of new blood vessels derived from tumor cell. Real-time PCR results showed that KOS could suppress the mRNA expression of human VEGF, bFGF, bFGFR and CD105 in MCF-7 xenograft tumor. All these results indicated that KOS has anti-tumor and anti-angiogenic activity in vivo and in vitro. Especially K has the potency to inhibit the differentiation of tumor cell to blood vessel endothelial cell. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:359 / 367
页数:9
相关论文
共 35 条
[1]   In vivo growth-inhibition of Sarcoma 180 tumor by alginates from brown seaweed Sargassum vulgare [J].
Alves de Sousa, Alessandra Paula ;
Torres, Marcia Rocha ;
Pessoa, Claudia ;
de Moraes, Manoel Odorico ;
Rocha Filho, Francisco Dario ;
Negreiros Nunes Alves, Ana Paula ;
Costa-Lotufo, Leticia Veras .
CARBOHYDRATE POLYMERS, 2007, 69 (01) :7-13
[2]   Cellular abnormalities of blood vessels as targets in cancer [J].
Baluk, P ;
Hashizume, H ;
McDonald, DM .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2005, 15 (01) :102-111
[3]   The angiogenic process as a therapeutic target in cancer [J].
Bridges, Esther M. ;
Harris, Adrian L. .
BIOCHEMICAL PHARMACOLOGY, 2011, 81 (10) :1183-1191
[4]   Angiogenesis in life, disease and medicine [J].
Carmeliet, P .
NATURE, 2005, 438 (7070) :932-936
[5]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[6]   Depolymerized products of λ-carrageenan as a potent angiogenesis inhibitor [J].
Chen, Haimin ;
Yan, Xiaojun ;
Lin, Jing ;
Wang, Feng ;
Xu, Weifeng .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2007, 55 (17) :6910-6917
[7]   FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? [J].
Fischer, Christian ;
Mazzone, Massimiliano ;
Jonckx, Bart ;
Carmeliet, Peter .
NATURE REVIEWS CANCER, 2008, 8 (12) :942-956
[8]   WHAT IS THE EVIDENCE THAT TUMORS ARE ANGIOGENESIS DEPENDENT [J].
FOLKMAN, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (01) :4-6
[9]   ANTI-ANGIOGENESIS - NEW CONCEPT FOR THERAPY OF SOLID TUMORS [J].
FOLKMAN, J .
ANNALS OF SURGERY, 1972, 175 (03) :409-&
[10]  
Gerber HP, 2005, CANCER RES, V65, P671